SIT improves glycemic control by slowing the inactivation of incretin hormones, increasing insulin synthesis and release from pancreatic beta cells, and lowering glucagon secretion, all factors that can eventually improve the clinical outcomes of COVID-19 patients. The gene discussed is GCG; the disease is COVID-19.